Cloudbreak Pharma reported findings from a market research survey suggesting that pinguecula significantly affects patients' quality of life and that there is substantial interest in a prescription treatment option for the condition, which currently lacks any FDA-approved pharmaceutical therapies.

The survey, conducted by an independent third-party market research firm during April and May 2026, included 1,020 U.S. adults aged 35 to 80 who had visited an eye care professional within the previous 5 years. Participants completed an internet-based questionnaire examining their experience with pinguecula and their interest in potential treatment options.

According to the survey results, approximately 10% of respondents self-identified as currently having pinguecula and reported being under the care of an eye care provider for the condition. Cloudbreak noted that the prevalence aligns with published epidemiologic data for moderate-to-severe disease. Published studies have also shown that the incidence of pinguecula increases with age and may affect roughly half of older adults.

Among respondents with pinguecula, more than three-quarters described the condition as "moderately or greatly bothersome." Commonly reported symptoms included ocular irritation, itching, and redness. Patients also identified several environmental factors that exacerbated symptoms, including allergies, dry or hot weather, excessive light exposure, smoking, and wind.

Interest in a prescription treatment option was also assessed. When informed that no FDA-approved pharmaceutical therapy currently exists for pinguecula, respondents rated their interest in a potential prescription treatment at an average of 3.4 on a 0-to-4 scale, indicating moderate-to-high interest.

“These data highlight the significant unmet need that we are working to address with CBT-004. We observed impressive efficacy in our phase 2 study, notably the statistically significant reductions in hyperemia and foreign body sensation from baseline that were seen as early as the first study visit on day seven," said Abu Abraham, MD, Chief Medical Officer at Cloudbreak Pharma. "We plan to build upon these compelling results as we initiate a rigorous and efficiently designed phase 3 program early next year.”

Cloudbreak stated that it intends to submit the complete survey findings for publication in a peer-reviewed medical journal in the coming months.